Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN)
Conditions
- Head and Neck Cancer
- Squamous Cell Carcinoma
- Oral Cavity Cancer
- Oropharyngeal Cancer
- Laryngeal Cancer
- Sinonasal Squamous Cell Carcinoma
- HPV (Human Papillomavirus)-Associated Carcinoma
- Skull Base Tumors
- HPV 16 Positive Oropharyngeal Tumors (OPC)
Interventions
- DRUG: Toripalimab + Chemotherapy
- DRUG: Toripalimab
- RADIATION: Chemoradiotherapy or radiation
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Collaborators